Hillman Cancer Center

Pittsburgh, Pennsylvania 15232

4 studies enrolling now · 58 studies all time

What they study most

Acute Myeloid Leukemia, Adenocarcinoma, Advanced Solid Tumor, Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Borderline Resectable Pancreatic Cancer, Breast Abnormalities, Breast Cancer, Cancer, Cancer of Lung, Cancer of Ovary, Cancer of the Lung, Cancer of the Ovary

Studies at this site

• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Recruiting now
• Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors — Recruiting now
• Detection of Genetic Markers of Lung Cancer — Recruiting now
• Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia — Recruiting now
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma — Running, not enrolling
• Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines — Withdrawn before enrolling
• A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease — Running, not enrolling
• Study of Outcomes of Radiofrequency Ablation of Lung Tumors — Paused
• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation — Running, not enrolling
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) — Completed
• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies — Completed
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early
• Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib — Completed
• Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence — Stopped early
• A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer — Completed
• Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma — Completed
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) — Completed
• A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. — Withdrawn before enrolling
• A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML — Completed
• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting — Completed
• Treatment of Advanced Melanoma With MK-3475 and Peginterferon — Completed
• Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b — Completed
• Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year — Completed
• BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab — Stopped early
• Melanoma Molecular Profiling Analysis — Completed
• A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer — Completed
• Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma — Completed
• Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) — Completed
• Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine — Completed
• Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer — Stopped early
• A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach — Withdrawn before enrolling
• Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma — Completed
• Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas — Completed
• Phase II Study of RAD001 Head and Neck Cancer — Stopped early
• Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) — Completed
• Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma — Stopped early
• A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer — Withdrawn before enrolling
• A Study of Imatinib and Docetaxel in Prostate Cancer — Completed
• A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer — Withdrawn before enrolling
• CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors — Completed
• Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma — Completed
• Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma — Stopped early
• The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease — Completed
• MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer — Completed
• Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer — Completed
• SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma — Withdrawn before enrolling
• Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia — Completed
• Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family — Completed
• SBRT + TACE for Primary Hepatocellular Carcinoma — Withdrawn before enrolling